Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806455 | 0.81 | PTGER4 (0.47) | CA12CA9CA1CA2CA7 | |
| SCHEMBL504060 | 0.80 | NR1H2 (0.43) | CA12CA9CA1CA2CA7 | |
| SCHEMBL13440433 | 0.80 | CA12 (0.46) | CA12CA9CA1CA2CA7 | |
| SCHEMBL3417559 | 0.79 | NR1H2 (0.46) | CA12CA9CA1CA2CA7 | |
| SCHEMBL9751229 | 0.79 | NR1H2 (0.46) | CA12CA9CA1CA2CA7 | |
| SCHEMBL14958500 | 0.78 | CA12 (0.39) | CA12CA9CA1CA2CA7 | |
| SCHEMBL3807234 | 0.76 | CA12 (0.46) | CA12CA9CA1CA2CA7 | |
| SCHEMBL82972 | 0.76 | GABRA1 (0.45) | CA12CA9CA1CA2CA7 | |
| SCHEMBL193750 | 0.74 | CA12 (0.50) | CA12CA9CA1CA2CA7 | |
| SCHEMBL1463156 | 0.74 | CA9 (0.50) | CA12CA9CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845810-B2 | Silicon glycan and method of preparing same | DOW SILICONES CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220395447-A1 | PERSONAL CARE COMPOSITION COMPRISING A SILICON GLYCAN | ROHM AND HAAS COMPANY | 2022-12-15 | — | — | US | disclosed |
| EP-4061854-A1 | SILICON GLYCAN AND METHOD OF PREPARING SAME | Dow Silicones Corporation (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-3906262-A1 | SILICON GLYCAN AND METHOD OF PREPARING SAME | Dow Silicones Corporation (US) | 2021-11-10 | — | — | EP | disclosed |
| WO-2021118775-A1 | PERSONAL CARE COMPOSITION COMPRISING A SILICON GLYCAN | ROHM AND HAAS COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021101677-A1 | SILICON GLYCAN AND METHOD OF PREPARING SAME | DOW SILICONES CORPORTION (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021101679-A1 | METHOD OF PREPARING A SILICON GLYCAN | DOW SILICONES CORPORATION (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2020142344-A1 | SILICON GLYCAN AND METHOD OF PREPARING SAME | DOW SILICONES CORPORATION (US) | 2020-07-09 | — | — | WO | disclosed |
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2598171-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2598170-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. | 2013-05-23 | — | — | US | disclosed |
| WO-2012015681-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015687-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. | 2011-12-08 | — | — | US | disclosed |
| EP-2391646-A1 | CRYSTALLINE INSULIN-CONJUGATES | Smartcells, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088300-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | CA12 98/4885CA9 263/4885CA1 357/4885 |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | CA12 98/4885CA9 263/4885CA1 357/4885 |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | IAPP, INSR, GPR119 | CA12 470/4885CA9 651/4885CA1 1911/4885 |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | ALK, ABL1, ERBB3 | CA12 2345/4885CA9 1347/4885CA1 3296/4885 |
| US-20220395447-A1 | PERSONAL CARE COMPOSITION COMPRISING A SILICON GLYCAN | CUTA, SCLY, YWHAZ | CA12 986/4885CA9 976/4885CA1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.